Myeloproliferative Disorders Treatment Market experiencing steady growth driven by 2037
The global Myeloproliferative Disorders (MPD) Treatment Market was worth USD 6.9 billion in 2024 and is expected to grow to USD 15.5 billion by 2037, showing a steady annual growth rate of 7.6% between 2025 and 2037. This growth is mainly driven by a rise in blood-related cancers, greater awareness among both patients and doctors, and the increasing use of advanced targeted therapies. The expansion of healthcare infrastructure and ongoing R&D efforts further support the market trajectory. Myeloproliferative Disorders Treatment Industry Demand Myeloproliferative disorders are a group of rare blood cancers characterized by the abnormal production of blood cells in the bone marrow. Common subtypes include Polycythemia Vera (PV) , Essential Thrombocythemia (ET) , Myelofibrosis (MF) , and Chronic Myeloid Leukemia (CML) . These disorders are chronic and often progressive, requiring long-term and often lifelong treatment. The need for MPD treatment is increasing because of se...